Pharmacist Anna Müller-Schöll

Bild Anna Müller-Schöll

Institute of Pharmacy

Clinical Pharmacy & Biochemistry

Address
Kelchstr. 31
Room 138 A
12169 Berlin
Email
anna.mueller-schoell[at]fu-berlin.de

Curriculum Vitae

since 07/2018

Doctoral student at the Graduate Research Training Program “PharMetrX: Pharmacometrics & Computational Disease Modelling“ at the Dept. of Clinical Pharmacy & Biochemistry supervised by Prof. Dr. Charlotte Kloft at the Freie Universitaet Berlin

07/2018

Registered Pharmacist

11/2017-04/2018

Internship in pharmacy ‘Apotheke am Helmholtzplatz’, Berlin

05/2017-10/2017

Internship at Pfizer Pharma GmbH, Berlin

09/2015-04/2017

Student research fellow in the Analytics & Metabolism group of Prof. Dr. Parr in the Department of Pharmaceutical Chemistry, Freie Universität, Berlin

02/2014

Internship in the ‚Spitzweg‘ Pharmacy, Stuttgart

08/2013

Internship in the hospital pharmacy of the Robert-Bosch-Hospital, Stuttgart

04/2013-04/2017

Studies of Pharmacy at the Freie Universität, Berlin

09/2012-02/2013

Internship in the project CommentVisions, addressing climate change and renewable energies, Euronews, London, United Kingdom

06/2012

Abitur at Karlsgymnasium Stuttgart

The focus of my research is to optimise modern anticancer drug treatment for the individual patient by combining therapeutic drug monitoring with a pharmacometric modelling & simulation approach.


Over the past 20 years, anticancer drug treatment has changed substantially from mostly untargeted, cytotoxic intravenous chemotherapy to novel therapeutic options like monoclonal antibodies, targeted oral anticancer drugs (tOADs) and immunotherapy. Although this change in treatment paradigm has improved the prognosis of many cancers dramatically, there are still some challenges to address:

Project 1: Targeted oral anticancer drugs (tOADs)

The field of tOADs is rapidly advancing and includes targeted antihormonal drugs, protein kinase inhibitors (KIs) and others. With 38 compounds approved since 2001, tyrosine kinase inhibitors (TKIs) form the biggest and fastest evolving subclass, targeting specific mutations, involved in a variety of cancers. tOADs typically show complex pharmacokinetics, a narrow therapeutic window and a high potential for (serious) adverse events. Nevertheless, at the currently practised “one-dose-fits-all” approach, every patient receives the same dosing regimen, ignoring the aforementioned complexities and resulting in up to 16-fold different exposures in individual patients. While subtherapeutic drug concentrations can lead to loss of efficacy, supratherapeutic drug concentrations can result in severe adverse reactions and ultimately in low adherence or even treatment discontinuation. In my work, I research on opportunities to individualise dosing regimens for tOADs based on patient-specific characteristics, drug properties and established or promising therapeutic targets, using model-informed precision dosing (MIPD). MIPD is based on the of use pharmacokinetic/pharmacodynamic (PK/PD) modelling and simulation to estimate population and patient-individual PK/PD parameters, to assess the probability of therapeutic target attainment under different dosing regimens and to make rational choices for the (initial) dosing of patients. Ultimately, this allows choosing the right dose for the individual patient, thereby maximising treatment efficacy and minimising toxicity.
Currently, I focus on the antihormonal drug tamoxifen and on tyrosine kinase inhibitors.

Project 2: Chimeric antigen receptor T cells (CAR-T cells)

CAR-T cells are an exciting new treatment option in the field of cancer immunotherapy. In short, T cells are extracted from a patient’s blood and genetically engineered to express a synthetic chimeric antigen receptor (CAR), targeting the patient’s tumour cells. After a 1-2 week expansion period, the manufactured T cells are infused back into the patient, where they specifically detect and kill cancer cells. While there has been remarkable success in the treatment of several forms of blood cancer, open challenges remain: While CAR-T cells rapidly expand and persist for years in some patients, they do not survive in others, resulting in loss of efficacy and cancer progression. Several factors might influence the expansion and, most importantly, long-term persistence of CAR-T cells. These include the frequencies of distinct CAR-T cell phenotypes in the infusion product, type and intensity of lymphodepleting chemotherapy, tumour burden and levels of several cytokines. In this project, by applying a systems-driven semi-mechanistic modelling & simulation framework, I aim to investigate the relevance of aforementioned factors for CAR-T cell expansion and persistence, in order to explore rational strategies towards increased treatment success.